

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES [ISSN: 0975-4725; CODEN(USA): IJPS00] Journal Homepage: https://www.ijpsjournal.com



Case Study

Study Of Adverse Drug Reaction Of Paracetamol Dose


Atharv Gangarde*, Kiran Bibave

S.S.P. Shikshan Sanshtas Siddhi College of Pharmacy, Newale Wasti Chikhali-411062.

ARTICLE INFO	ABSTRACT
Received: 27 May 2024 Accepted: 06 June 2024 Published: 07 June 2024 Keywords: Acetaminophen, Paracetamol, case study, Adverse Drug Reaction DOI: 10.5281/zenodo.11521608	Acetaminophen, generally known as paracetamol, is one of the most commonly used over-the-counter analgesics and antipyretics globally. It is frequently administered for the relief of pain and fever in both adults and children. However, calculating the proper dosage of paracetamol can be difficult due to a variety of factors such as age, weight, underlying medical conditions, and concurrent drugs. This presentation seeks to offer a comprehensive evaluation of the optimal paracetamol dosage using the most recent research and guidelines available till September 2021. The review investigates paracetamol's pharmacokinetics and mechanism of action, focusing on its therapeutic effects as well as potential side effects. It discusses the significance of precisely estimating the optimum dose to provide maximum efficacy while reducing the danger of harm.

INTRODUCTION

Paracetamol is an analgesic and fever reducer. It is used to treat a wide range of symptoms, including headaches, muscle aches, toothaches, colds, and flu. Paracetamol is available over the counter in a variety of forms, including tablets, capsules, liquids, and suppositories. Adults should take 1,000 milligrams (mg) of paracetamol every 4 to 6 hours, with a maximum daily dose of 4,000 mg. For children, the dose is determined by their weight and age. It is critical to follow the label's instructions attentively and not exceed the suggested dose. If you take too much paracetamol, it can be hazardous. Paracetamol should not be taken by persons who are allergic to it or have liver or kidney problems. It should also not be taken by pregnant or lactating women unless prescribed by a doctor. If you are on other medications, consult your doctor before using paracetamol. Some drugs may interact with paracetamol, increasing the risk of unwanted effects. When used exactly as prescribed, paracetamol is both safe and effective. However, it is critical to be informed of the potential side effects and hazards before using it.



*Corresponding Author: Atharv Gangarde

Address: S.S.P. Shikshan Sanshtas Siddhi College of Pharmacy, Newale Wasti Chikhali-411062

Email : atharvgangarde29@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Paracetamol (Panadol, Calpol, Alvedon) is an analgesic and antipyretic medication used to alleviate mild to moderate pain and fever. It is widely used as a component in cold and flu treatments, although it can also be used alone. Paracetamol is the same as acetaminophen (Tylenol). The drug's name is Paracetamol, as assigned by the International Nonproprietary Name (INN) generic name system. In Europe, Australia, New Zealand, and India, the medicine is referred to as paracetamol. Acetaminophen is the generic name assigned under the United States Adopted Names (USAN) system.

In the United States, Canada, and Japan, the drug is known as acetaminophen. Typically, the INN and USAN generic names for a medicine are identical and do not differ across nations. Paracetamol was developed in 1878, but it wasn't extensively utilized until the 1950s. Today, paracetamol is one of the most often used pain relievers in the world. This medicine is available in both branded and generic versions. Paracetamol is a popular pain reliever and fever reducer, available both over the counter and on prescription. It has distinct clinical ล pharmacological profile, including strong analgesic and Antipyretic effects with no or little anti-inflammatory efficacy, as well as modest gastrointestinal, renal, and vascular adverse effects. Paracetamol has long been suggested as the first-line medication in pain management guidelines. It is often used to treat headaches, muscle pain, menstrual cramps, toothaches, and the common cold. Paracetamol is available in pills, capsules, liquid solutions, and suppositories. The proper dosage of paracetamol varies according to age, weight, and the severity of the ailment being treated. To obtain detailed dose directions, see the product package or visit a healthcare practitioner. Here is a summary of the history of adverse medication events related with paracetamol use:

- 1. Early Recognition: In the late 1960s and early 1970s, reports surfaced associating high dosages of paracetamol to liver damage. This acknowledgment raised awareness and prompted more inquiries into the drug's possible hazards.
- 2. Regulatory actions: Regulatory bodies, including the FDA and EMA, have taken action to address the dangers of paracetamol based on developing evidence. These included establishing maximum daily doses and reinforcing warning labels.
- 3. Hepatotoxicity: Paracetamol overdose, especially when used in excess of the prescribed daily dosage or in combination with alcohol, can result in severe liver damage. The most common adverse medication reaction associated with paracetamol is hepatotoxicity. It is primarily caused by the development of a poisonous metabolite known as N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione and induces oxidative stress in the liver.
- 4. Therapeutic Misadventure: Adverse responses to paracetamol can also occur when patients accidentally exceed the recommended dosage or consume many paracetamol-containing medicines concurrently without recognizing it. This inadvertent overdose can result in liver damage.
- 5. Recognizing Symptoms: Paracetamol toxicity symptoms may not appear quickly and may take several days to show. Initially, patients may experience nonspecific symptoms such as nausea, vomiting, and malaise. As liver damage worsens, symptoms of hepatotoxicity such as jaundice, stomach discomfort, and increased liver enzymes may occur.
- 6. Regulatory Measures: Over time, regulatory bodies have monitored paracetamol's safety and introduced additional safeguards to reduce the likelihood of adverse reactions. These

include further decreasing the maximum recommended daily dose and giving better directions on dosing and duration of use.

An adverse medication reaction.

An adverse drug reaction (ADR) is defined as "an appreciably harmful or unpleasant reaction resulting from an intervention related to the use of a medicinal product; adverse effects usually predict hazard from future administration and warrant prevention, specific treatment, dosage regimen modification, or product withdrawal." Adverse drug reactions (ADRs) are unplanned, adverse occurrences associated with the use of medications that occur as a cause and during a considerable proportion of unscheduled hospital admissions. Since 2012, the definition has expanded to encompass reactions caused by error, misuse, or abuse, as well as suspected reactions to unlicensed or off-label drugs, in addition to the authorized use of a medicinal product in regular doses.

A thorough medication history can help a prescriber comprehend the patient's previous experiences with drug therapy, notably detecting previous ADRs that may preclude re-exposure to the medicine. Preventing ADRs requires avoiding therapy in patient cohorts with a higher vulnerability or administering treatment under a therapeutic strategy that decreases the probability of an adverse effect (for example, coadministration of other medications, monitoring blood test results). Spontaneous reporting (via the Yellow Card Scheme in the UK) of suspected ADRs is a vital aspect of pharmacovigilance, however ADRs are significantly underreported across healthcare settings and sectors. If in doubt, send a report. [2]Seminal studies conducted in the late twentieth and early twenty-first centuries in the United States and the United Kingdom established that ADRs are a prevalent occurrence in clinical practice, including as a cause of unscheduled hospital admissions, happening

during hospitalization, and presenting after discharge. The prevalence of ADRs has remained largely stable throughout time, with data indicating that 5% to 10% of patients may experience an ADR at admission, during hospitalization, or after discharge, despite numerous prevention measures. The incidence of occurrences is inextricably linked to the method employed to identify them, and the vast majority of ADRs do not produce substantial systemic symptoms. Antiplatelet, anticoagulant, cytotoxic, immunosuppressant, diuretic, antidiabetic, and antibiotic medications have all been linked to ADR-related hospitalizations. Fatal ADRs are frequently caused by hemorrhage, with an antithrombotic/anticoagulant combined with a anti-inflammatory nonsteroidal medicine (NSAID) being the most common probable cause. **Types of Adverse Drug Reactions:**

- Dose-related
- Allergic
- Idiosyncratic

Dose-related adverse medication reactions are an exaggeration of the medicine's therapeutic effects. A person using a blood pressure medicine, for example, may feel dizzy or light-headed if the treatment lowers blood pressure too quickly. A diabetic may experience weakness, sweating, nausea, and palpitations if insulin or another antidiabetic treatment lowers blood sugar levels too much. This type of adverse medication reaction is usually anticipated, but it might also be inevitable. It can happen if a drug dose is excessively high, if the person is extremely sensitive to the medicine, or if another drug delays the metabolism of the first drug, increasing its level in the blood. Dose-related reactions might be severe or mild, although they are rather common.

Allergic medication reactions are not doserelated but do require prior exposure to the substance. Allergic reactions occur when the body's immune system responds inappropriately to a substance (also known as sensitization). After a person has been sensitized, subsequent exposures to the substance cause one of several types of allergic reactions. Doctors may use skin tests to predict allergic medication reactions.

Idiosyncratic adverse medication responses arise from processes that are currently unknown. This form of adverse medication reaction is quite unpredictable. Rashes, jaundice, anemia, a reduction in white blood cell count, kidney damage, and nerve injury that may impair vision or hearing are some of the adverse medication reactions seen.

Some adverse drug reactions are unrelated to the medication's therapeutic impact yet are frequently foreseeable because the underlying mechanisms are well recognized. For example, stomach discomfort and bleeding frequently occur in patients who routinely use aspirin or other nonsteroidal anti-inflammatory drugs. These drugs inhibit the formation of prostaglandins, which protect the digestive tract from stomach acid.

Type of reaction	Mechanism/Example
Type A (Augmented)	Predicted from the known pharmacology of the drug. These reactions are dose-dependent: examples are bleeding with anticoagulants
Type B (Bizarre)	Reactions are not predicted from the known pharmacology of the drug. They appear (but actually are not) relatively dose-independent, as very small doses might already elicit symptoms. They include immune-mediated side-effects like maculopapular exanthema, but also other hypersensitivity reactions, like aspirin-induced asthma
Type C (Chemical/Chronic)	Which are related to the chemical structure and its metabolism, e.g. paracetamol hepatotoxicity.
Type D (Delayed)	Which appear after many years of treatment, e.g. bladder carcinoma after treatment with cyclophosphamide
Type E (End of treatment)	Occur after drug withdrawal, e.g. seizures after stopping phenytoin

Type of reaction Mechanism/Example

Fig 2. Overview of types of ADR's

SEVERITY OF ADRS:

CRITERIA FOR IDENTIFYING ADRs:

ADR identified by physicians will be considered and will be included in the study.

ANALYSIS OF ADRs:

Nature and description of ADDRs reported.

CAUSALITY ASSESSMENT OF ADR BASED ON ALGORITHM:

The degree of association of an adverse of an adverse reaction with a drug is done with the help of Naranjo's algorithm.

After the causality assessment has been done, the severity of the ADR is analyses using adapted Hart wig severity scale.

Naranjo's algorithm – ADR probability scale

The Naranjo Algorithm, or Adverse Drug Reaction Probability Scale, is a method by which to assess whether there is a causal relationship between an identified untoward clinical event and



a drug using a simple questionnaire to assign Adverse Drug Reaction Probability Scale probability scores.

Question	Yes	No	Do Not Know	Score
1.Are there previous conclusive reports on this reaction?	+1	0	0	
2. Did the adverse event appear after the suspected drug wasadministered?	+2	-1	0	
3. Did the adverse event improve when the drug was discontinued, or a specific antagonist was administered?	+1	0	0	
4. Did the adverse event reappear when the drug wasreadministered?	+2	-1	0	
5. Are there alternative causes that could on their own have caused the reaction?	-1	+2	0	
6. Did the reaction reappear when a placebo was given?	-1	+1	0	
7. Was the drug detected in blood or other fluids in concentrationsknown to be toxic?	+1	0	0	
8. Was the reaction more severe when the dose was increased orless severe when the dose was decreased?	+1	0	0	
9. Did the patient have a similar reaction to the same or similardrugs in any previous exposure?	+1	0	0	
10. Was the adverse event confirmed by any objective evidence?	+1	0	0	
		Tota	l Score:	

Score	Interpretation of Scores
Total Score ≥9	Definite. The reaction (1) followed a reasonable temporal sequence after a drug or in which a toxic drug level had been established in body fluids or tissues, (2) followed a recognized response to the suspected drug, and (3) was confirmed by improvement on withdrawing the drug and reappeared on re exposure.
Total Score 5 to 8	Probable. The reaction (1) followed a reasonable temporal sequence after a drug, (2) followed a recognized response to the suspected drug, (3) was confirmed by withdrawal but not by exposure to the drug, and (4) could not be reasonably explained by the known characteristics of the patient's clinical state.
Total Score 1 to 4	Possible. The reaction (1) followed a temporal sequence after a drug, (2) possibly followed a recognized pattern to the suspected drug, and (3) could be explained by characteristics of the patient's disease.
Total Score ≤0	Doubtful. The reaction was likely related to factors other than a drug.

The Scale is classified as:

- 1. Mild: A reaction that does not required treatment or hospital stay.
- 2. Moderate: A reaction that requires treatment and prolongs hospitalization by at least one day. 3.Severe: A reaction that is potentially life threatening or contributes to the death of patient is permanently disabling requires intensive medical care or results in a congenital anomaly cancer or unintentional overdose.

Preventability of ADRs:

Complete preventability of ADR is not possible, but some of the ADR can be preventable if that ADR can give at least one answer of Schumock and Thornton Scale.

Predictability of ADRs:

Patients who have had the drug on previous occasion(s): If the drug was previously welltolerated at the same dose and route of administration, the ADR is NOT PREDICTABLE; there was a history of allergy or



previous reaction to the drug, the ADR is PREDICTABLE. Patients who have never had the drug previously: Incidence of the ADR reported in product information or other literature determines its predictability.

Observation

Following the eighth dose of paracetamol IV (1gm/1000ml), the patient developed red rashes on their upper limbs. Potassium chloride injection was a concurrent medication that was terminated as soon as rashes appeared. For the response, injection Avil was administered.

	The Party of the P		PAPEP	fulpiture (r	Git klant		In succession	FOR	AHC / NS	0.00	E1:		
Image: Section 1 And the section 1 Image: Section 1 And the section 1 <td< th=""><th>THE PARTY OF THE P</th><th></th><th></th><th>allow-up E</th><th>ale Cl</th><th>-</th><th>Ren. No. / 1</th><th>PD No. / C</th><th>PO No. / C</th><th>IL HULL</th><th></th><th></th><th></th></td<>	THE PARTY OF THE P			allow-up E	ale Cl	-	Ren. No. / 1	PD No. / C	PO No. / C	IL HULL			
	The Party of the P		-			-	ABART DESIGNER	Peres .		-			
And you will a lower (0.16.4) And you will you will be an interest of the second interest of th		Trentation is ago in more of hethin & G. 79 Ar											
Normality Source - Source Market restance Source -							12. Ruthratt	The supplication of the su	One wire on				
Internet and internet inte	42 - 3 0	and the	ALL	-	Contraction in which the	1.1.3	ASHINE.						
The second set of the second sec	and the second second	OCCUPATION OF	0H	0.0-1	6-22								
The sector instructure requires and the sector of the	CONTRACTOR STOLE	mate (dates	and proved	9-D -1	7 - 20								
After the test for advect radius on appendix intervention (strength and the second radius) is advected radius on appendix intervention (strength and the second radius) intervent intervention (strength and the second radiu				anto 2 a	NV:					1000	NOC YOUR	-	
Image: Second	Committee Diversification	150	ADSC 0	& PA	aceta	n.DI	an Relovan	(medical /	medication	nistory I dysfur	(n-g. etc.)	and the second s	h.
Image: Series and red reduces on dependence Image: Series and red reduces on dependence Image: Series and reduces and reduces on dependence Image: Series and reduces and reduces on dependence Image: Series and reduces and reduces and reduces Image: Series and reduces and reduces and reduces Image: Series and reduces and reduces Image: Series and reduces Image:	After the H	Cites of	redma	Jurer.	ed (212	(22.9	posporary, 8	adenni, *	stanc' iana	201			
Binder get term	m (39/1000	11 1 1 M		Sec. 1	m dep	10	625						
Im AS	a work 90	or re	A Press	In East - 1									
Control of the centred of the centred of the centre o	Marchiter S										N- Ch Cala	AND D	ick anymouth)
Control of the second of	Lambs	and the second	neo w	as Ir	v porce	EX-) Lan	14. Seriman	ess of the	eartige : N	DCin DCin	annitai-ann	outy	
Build Brownerding Dub Brownerding Dub Brownerding Dub Brownerding Dub Brownerding Bit Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding Brownerding B	CONCONVINO!	ne or	wat to	to ppe	d at si	16197	Citiesath (dd/	mmenrer.		Contrain.	- Bell S Park		
10 AVIL WAL 9000 for the frequency fraction 13. Outcome Becauvered with require One accurate 10 AVIL WAL 9000 for the frequency fraction Becauvered with require One accurate One accurate 10 AVIL WAL 9000 for the fraction Becauvered with require Becauvered with require One accurate 10 Becauvered with require Becauvered with require Becauvered with require Canvality 10 Becauvered with require Becauvered with require Becauvered with require Canvality 10 Becauvered with require Becauvered with require Canvality 11 Becauvered with require Canvality 12 Becauvered with require Canvality 13 Becauvered with require Canvality 14 Becauvered with require Canvality 15 Becauvered Becauvered with require 14 Becauvered with require Canvality 15 Becauvered Becauvered with require 16 Becauvered Becauvered with require 16 Becauvered Becauvered Becauvered 16 Becauvere							Duinentalina	erneg. Horr-Initial	Prolunged	Dates	er Madically	inte	artant
Direct Direction Direction <thdirection< th=""> <thdirection< th=""> <thdire< td=""><td>as round</td><td>LO.C</td><td>and the second</td><td>Sector-</td><td>the en</td><td>See an</td><td>AR Didawa</td><td>eri</td><td></td><td></td><td></td><td></td><td></td></thdire<></thdirection<></thdirection<>	as round	LO.C	and the second	Sector-	the en	See an	AR Didawa	eri					
Of Parted Directory with sequence Directory with sequence Directory of the sequence <thdirectory of="" sequence<="" th="" the=""> <thdirectory of="" sequenc<="" td="" the=""><td>THE MARTL N</td><td>MARE</td><td>Buch</td><td>fre</td><td>The TO</td><td>act tos</td><td>Likeconstead</td><td>GReep</td><td>vering</td><td></td><td></td><td></td><td></td></thdirectory></thdirectory>	THE MARTL N	MARE	Buch	fre	The TO	act tos	Likeconstead	GReep	vering				
The standard of the standard in match in the first standard in the standard in								DRess	vered with	sequili	ate Dunka	now n	COLUMN STREET
Bit of the section of the section (press in the sectin the section (press in the section (press in the sectio			COLUMN DATE	12030	1000	-	and the second	- Hime	Total and	Tad	ication	C	aunality
Barrent Barent Barrent Barrent Barrent Barrent Barrent Barrent Barrent Barren	REPORTED MERICAN	anufacte	Butch No.	Expiry	Dese	Route	Frequency	Date	Date	1.10		As	sassment
Mar. No. Mar. Mar. </td <td>Manne</td> <td>141</td> <td>1</td> <td>(if</td> <td>_</td> <td></td> <td></td> <td></td> <td>Stopped</td> <td></td> <td></td> <td>_</td> <td></td>	Manne	141	1	(if	_				Stopped			_	
Beginner Construction 12 (2000) 10 55471 18.10.12 Divergence Divergence Bestimmer Status Construction Construction Construction Divergence Divergence <td>- Conserved</td> <td></td> <td>No.</td> <td>known)</td> <td>To Lund</td> <td>-</td> <td>Fed-4</td> <td>17.10.00</td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td>	- Conserved		No.	known)	To Lund	-	Fed-4	17.10.00				-	-
Description: Schwarzenic Manager 4.5 m/s 1 1.4 m/s Device Manager Example: Schwarzenic Manager 0.6 m/s 5.6 m/s 6.0 m/s 10. Reaction reappointed after reintradiuction of suspected after reintradiuction of suspected medication (prover UN) Energy Dase Dase moli methods Manager Dase moli methods Manager Dase moli methods Manager	AGUTMOL TV A	CONTRA					and the second sec					-	
Protein Carity Carity <thcarity< th=""> <thcarity< th=""> <thcarity< t<="" td=""><td>THE REFLICE CLIMPLE</td><td>CARGE THE H</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></thcarity<></thcarity<></thcarity<>	THE REFLICE CLIMPLE	CARGE THE H											
Trans after section (prese n/s) So and the second (prese n/s) So and the sectin (prese n/s) So and the s								18-10-22	-				
Story entraceous Dose intraceous Dose relations Dose procession (Free introduces) Dose (Free introduces) Dose (Free introduces) Bits Dose prove the changed Dose the pope the changed Dose pope the pope the changed Ves No Effect withown (Free introduces) Dose prove the changed Dose pope the changed	and the second s	100 C	e miki					10. Heat	mon reappt	cation	ther reinfrac	ance G	on or
Stray Mittageneric Transferid Transferid Changed applicable Introduced Door Correction Correction Correction Introduced Introduced Correction Correction Correction Correction Introduced Door Correction Correction Correction Introduced Door Correction Correction Correction Introduced Door Roote Prequency (OD) Therapy Dates Indication Name Door Roote Prequency (OD) Therapy Dates Indication Name Door Roote Prequency (OD) Therapy Dates Indication Bit State Date Storted Date Storped Indication Date Started Date Storped Indication Indication		Statute of the second	TAXABLE INCOME.	Dose or	I No	it	Unknown				Effoct	200	
						utda		1			Bitknow	n	
Image: Second and the second					Roon	choon	4		1			1	1012010100
Len.ple+cd Name Does Roote Prequency (00, Therapy Dates Indication Name Does Roote Prequency (00, Therapy Dates Indication Stand / Generic) Does Roote Prequency (00, Therapy Dates Indication Stand / Generic) Does Roote Prequency (00, Therapy Dates Indication Stand / Generic) Does Roote Prequency (00, Therapy Dates Indication Stand / Generic) Does Roote Prequency (00, Therapy Dates Indication Stand / Generic) Date Started Date Stopped Indication Indication Stand / Generic) Does Roote Preventes Indication Stand / Generic) Does Roote Does Roote Does Stand / Generic) Does Roote Does Roote Does Roote Roote Stand Roote Does Tenall Clinical phoremodelogistry Roote None None None None None Noctpitolsciella Roote							A L	-				_	
Name Does Roste Frequency (OB, BD, etc.) Name Does Roste Frequency (OB, BD, etc.) Date Started Date Stopped Creater / General General General Date Started Date Stopped Tedication Creater / General General General Date Started Date Stopped Tedication Creater / General General General Date Started Date Stopped Tedication Creater / General General General Date Started Date Stopped Tedication Creater / General General General Date Started Date Stopped Tedication Creater / General General General Date Started Date Stopped Tedication Creater / General General General Date Started Date Started Date Started Tedication Creater / General General Started Date Started Date Started Tedication Creater / General Train Clin.(cal phormx6clogistr (General Monou General (General General Tedication Train Clin.(cal phormx6clogistr (General)		-						-	-			-	
Name (Hame / Generic) Does (Hame / Generic) Roote Prequency (00, BD, etc.) Therapy Dates Indication Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Stopped Date Started Stopped Date Started Stopped Date Started Stopped Date Started Date Started Stopped Not Pittopped Date Started Stopped Date Started Stopped Date Started Date Started Stopped Date Started Stopped Date Started Stopped Date Started Stopped			_	_	Lampl	erea		-	-			-	-
Name (Hame / Generic) Does (Hame / Generic) Roote Prequency (00, BD, etc.) Therapy Dates Indication Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Date Stopped Date Stopped Date Stopped Date Started Date Started Stopped Date Started Stopped Date Started Stopped Date Started Stopped Date Started Date Started Stopped Not Pittopped Date Started Stopped Date Started Stopped Date Started Date Started Stopped Date Started Stopped Date Started Stopped Date Started Stopped		and a second	100 m 100 m	Station 22	221000000	5779367	CONTRACTOR OF					-	
Orant / Generic) BD, etc.) Date Started Date Stopped Etc. GAUNCIC GOMEQ LV S-ED-1 LS 10-20. and Information I O. REPORTEX ONTAILS St. Name & Address I. DY. AtSECONY. Khirode Pin: Train Clin.col phor modelogisht (@ monul Contact No.9605D00540 hetp://ox.com. Occumitor: Charte at this report (dd/mm/ryyyy): 20-10 34- The patterning Personnel 1. The product ansated in strict confidence and producted by the fullest except. Submission of a report does not not be product ansated at contributed to the reaction. Submission of a report does not not be product ansated at contributed to the reaction.		Dose	Real						ade those u	ued to			
Chilinida Gonga IV Start 18 10-22 O. REPORTER ONTAILS Ste. Name & Address : DY Attackey Khirode Pin: Train Clin.cal pharmacelogist & monit Connect No. 9605026560 hetpitois. com. Occumator No. 9605026560 hetpitois. Occumator No. 960502660 hetpitois. Occumator No. 960502600 hetpitois. Occumator No. 960502600 hetpitois. Occumator No. 9605026000 hetpitois. Occumator No. 96050260000 hetpitois. Occumator N	(Brand / Generic)		1	1 1 1 S	D, etc.)	-	- Aller		in the second second		Contraction of		- 00
And Rene at Receiving Personnel : October 1:: Optimized on the product caused an cameribuled to the reaction. Bubmission of a report does not	the distant of a	Labir	A 122		f has a	1000	Carl State State	wate Ste	P.Sent.	_			
36. Name & Address : Dr. Atclocy Kbirods Pin: Tmail Clin.co.f phormacelogist (4 more) Context No.9665000366 hetpitots.com Occupation : Clin.co.f phormacelogist (4 more) Context No.9665000366 hetpitots.com Occupation : Clin.co.f phormacelogist (4 more) S7. Date of this report (44/mm/7yyy) 20 /0.34	C. CHINNEL	Howe	4 12	-	SERVE	18	10-22		-	-			
36. Name & Address : Dr. Aktiony Khirode Pin: Tmail Clin.co.phormacelogist (a mono Context No-965500946 hetpitoss com Occupation : C pharmatelegist senature Affra 37. Date of this report (dd/mm/yyyy): 20-10-34 million - The piller is included on strict confidence and protected to the failest extent. Submission of a report does not not never by final implication in the protected to the product encoded a captor does not not never by final implication on the protected.			-		_	-		-				-	
36. Name & Address : Dr. Aktiony Khirode Pin: Tmail Clin.co.phormacelogist (a mono Context No-965500946 hetpitoss com Occupation : C pharmatelegist senature Affra 37. Date of this report (dd/mm/yyyy): 20-10-34 million - The piller is included on strict confidence and protected to the failest extent. Submission of a report does not not never by final implication in the protected to the product encoded a captor does not not never by final implication on the protected.	and information (0.10	ERONTER OF	7305 2	-		-		-
Pin: Totali <u>Clinical phormacelogit</u> (<u>Anow</u> Contact No- <u>9605020976</u> <u>hotpitoss</u> <u>com</u> <u>Occupation</u> <u>C</u> <u>phormatelogit</u> <u>Superiore</u> <u>s</u> <u>com</u> <u>17</u> . Date of this report (dd/mm/yyyy) <u>20-10-32</u> Inflam contaction this report (dd/mm/yyyy) <u>20-10-32</u> Inflam contaction the product source and producted to the fullest extent. Submission of a report does not par anow in they any requirements on the product source and contributed to the reaction. Submission of						15. 4	Lama & Arist	0	01/10	CHARGE ST	a water	-	
Contert No. 9655555765 NOSPITOLS. COR- Occupation: C. Braythinists (g) Lt. Sensture : Occupating: Occupation: Occupation: Occupation: Occupa						1000	and a month	- M	MICIE	any	Relation	od.	L
Contert No-9655516762 NOSPITOLS CORE Contert No-9655516762 NOSPITOLS CORE Contert No-9655516762 NOSPITOLS CORE Contert No-9655516762 NOSPITOLS CORE Sector 2012 Nospital 2012 Nos						Pin			Internet	-		1.0.0	E. C. C.
occupation : C Charle Bitle 9114 Separature :						LT1MA P-	the Greek	in the	here	2-4-02-2	C Log	44	Car Incho
17. Date of this report (dd/mm/yyyy): 20-10-32 intermediate The patient's mention is sensed in strict confidence and protected to the failest extent. Submission of a report does no part are set toric any femal implication on the report.						Decon	untion C CL	Or the P	Jacob La	CTON.	as there	15	NC.
The partient's monthly is held in strict confidence and protected to the fullest extent. Submission of a report does no part are set here any local individual personnel or manufactures or the product caused or contributed to the reaction. Submission of						17. 7	Date of this	a second of	TO ALTE	3-grat	we -	山山	A. S. C.
alls an operation for monably is read in strict confidence and protected to the fullest extent. Submission of a report does no portage as here any legal implication on the reports.		caning P	Innocre	E./	-	- and	and be talls a	about (qu	/mm/yyy	A) 1	20-10	33	-
The second second second or monofecturer or the product caused or contributed to the receiption of a report does no second second second second second	THE REAL PROPERTY OF REAL	THE NEEDS	alley is teal	d in atrice	confidence	2010	(CHARTER PROPERTY)	THE OWNER WHEN		-			
Any full new supervises in the reporter. Submission of the resettory. Submission of any full ne supervised with Reporting Paras	antiating The patter		AL DOLLOUID	tel or mai	furfacturer e	tr the s	reduct course	ed de com	antonal s	Submi	stion of a	repo	ert does no
and a second for an and Alife Respecting Press	Tells an Opportunited on the	Henry legal	Implicate	the same life									
	In the second state of the	ing lenal	Implicato	so nn the	reporter.	LENE	Call Mar	Stand P	meater t	e inio e	réaction.	Furbo	nission of
	the an approximation the	Atte Bego	ettingi farmi	so ng Lhe	reporter.	Nen A		Alenan	inearea n	1 100	Hacton.	Suipt.	nission of

Fig 3. Adverse Drug Reaction Report



ľ	Naranjo Adverse Drug Reaction Probabilit	WES.	No	Do Not Enow	Score
ł	Curstion	+1	0	0	0
	are new previous conclusive reports on this reaction?	12	-1	a	+.2
t at	that the adverse recent approx after the suspected drug was advancement?	+1	0	0	+1
ł	Out the adverse reaction improve when the drug was discontinued or a sends antagenist was administrated?	+2	1	0	-1
ĩ	the situate event insupport when the drug was re-administered?	-1	+2	0	0
	Are there alternative causes (other than the drug) that could on their own take cauled the reaction?			-	1-1
ł	Did the traction mappear when a placebo was given?	-1	+3	0	+1
7	was the anug distocted in blood (or other fluids) in concentrations known to be tract?	+1	0	0	0
	to be the relation more severe when the dose was increased or less severe when the dose was detreased?	+1	0	0	0
	Did the patient have a similar reaction to the same or similar drugs in ony previous exposure?	+1	D	0	0
10	Was the athense event confirmed by any objective evidence?	+3	c	Ó	+1
		TOT	TAL SO	ORE:	4
toil Nac	ybod from: Naranyo CA et al. A method for estimating the probability of macof Ther 1981: 30: 279-245.	'adve	rse dri	ığ reacti	ons. Clin

Fig 4. Naranjo's scale

Patient Demographics

After the total dose of paracetamol IV (1gm/1000ml) is administered (8th dose) patient got red rashes on upper limbs. Concomitant drug was injection Potassium Chloride which was stopped as soon as rashes are observed. Injection Avil was given for the reaction.

Concomitant

Medications Potassium Chloride 40mg Suspected Medications

Brand Name - Potassium Chloride

Manufacturer- Medilife

Dose – 40mg

Route – Intravenous (IV) Frequency – STAT Date Started – 18/10/2022 Indication – Hypokalemia

Mechanism of action of Paracetamol

Prostaglandin synthesis inhibition: Cyclooxygenase (COX), an enzyme involved in prostaglandin synthesis, is weakly inhibited by paracetamol. Chemicals called prostaglandins are involved in inflammation and discomfort.

One possible mechanism of action for paracetamol is the activation of descending serotonergic pathways in the brain. The regulation of pain is influenced by these pathways.

Cannabinoid receptor involvement: According to some research, paracetamol may also function by attaching to cannabinoid receptors. Pain alleviation and other benefits are mediated by cannabinoid receptors. The exact mechanism of action of paracetamol is still being investigated. However, it is clear that paracetamol is a safe and



effective medication for pain relief and fever reduction.

Here are some more specifics regarding paracetamol's mode of action:

Prostaglandin synthesis inhibition: The COX enzyme has two isoforms, COX-1 and COX-2, which are both weakly inhibited by paracetamol. Prostaglandins are molecules that contribute to inflammation and pain, and they are produced by COX enzymes. By attaching to an enzyme site distinct from the one that is blocked by nonsteroidal anti-inflammatory medicines (NSAIDs), paracetamol inhibits COX enzymes. The reason paracetamol has less side effects than NSAIDs is due to this differential in binding.

One possible mechanism of action for paracetamol is the activation of descending serotonergic pathways in the brain. The regulation of pain is influenced by these pathways. When taking paracetamol, it causes an increase in the serotonin in brain. Cannabinoid receptor involvement: According to some research, paracetamol may also function by attaching to cannabinoid receptors. Pain alleviation and other benefits are mediated by cannabinoid receptors. When taken orally, paracetamol has the potential to bind and activate cannabinoid receptors. Pain alleviation results from its activation after that. Research is still ongoing to determine paracetamol's precise mode of action. Nonetheless, it is evident that paracetamol is a drug that is both safe and efficient for treating pain and lowering fever. The enzyme called prostaglandin H(2) synthetase (PGHS) is in charge of breaking down arachidonic acid into the unstable PGH(2). The constitutive PGHS-1 and the inducible PGHS-2 are the two main types of this enzyme. There are two locations for PGHS: a cyclooxygenase (COX) and peroxidase (POX) sites. The COX site requires a tyrosine-385 radical to convert arachidonic acid to PGG(2). The formation of a ferryl protoporphyrin IX radical cation from the reducing agent Fe(3+) at the POX

site is required for the conversion of tyrosine-385 to its radical state. Paracetamol functions as a reducing cosubstrate at the POX site, limiting the availability of the ferryl protoporphyrin IX radical cation. This action can be mitigated by the presence of hydroperoxide-producing lipoxygenase enzymes within the cell (peroxide tone) or by flooding the POX site with substrate such as PGG(2). Peroxide tone and swamping account for paracetamol's lack of peripheral analgesic, platelet, and anti-inflammatory effects. Paracetamol's actions could also be mediated via an active metabolite (p-aminophenol). Fatty acid amide hydrolase converts p-aminophenol to arachidonic acid, resulting in AM404. AM404 acts through cannabinoid receptors. It may also function via PGHS, particularly in brain regions with high levels of fatty acid amide hydrolase.




Fig 5. Mechanism of action of Paracetamol Acetaminophen (paracetamol) is widely thought to be a mild inhibitor of prostaglandin production. However, paracetamol's in vivo effects are comparable to those of selective cyclooxygenase-2 (COX-2) inhibitors. Paracetamol reduces PG concentrations in vivo, however unlike specific COX-2 inhibitors, it does not reduce rheumatoid arthritis inflammation. It does, however, reduce swelling following oral surgery in people and



inhibit inflammation in rats and mice. Paracetamol is a poor inhibitor of PG synthesis of COX-1 and COX-2 in broken cell systems; nevertheless, therapeutic dosages of paracetamol block PG synthesis in intact cells in vitro when arachidonic acid levels are low.

Paracetamol Dose for Pediatrics

Paracetamol is a drug that is widely used in children and is available without a prescription. Paracetamol is most commonly used to relieve pain and lower fevers. Panadol, Dymadon, and Panamax are some of the paracetamol brands available in Australia with children's formulations. While having a high temperature isn't always a bad thing because it boosts your immune system, it can be extremely painful. This is common with youngsters and can cause sleep disturbances for parents, brothers, and sisters. However, it is vital to understand that, while paracetamol can help patients feel better, it has little effect on the actual course of the underlying sickness.

Paracetamol is one of the most regularly used 'over-the-counter' medications, particularly for mild diseases that affect many youngsters. However, it is not often administered in the proper dosage, which might render it ineffective or hazardous. When used properly, paracetamol is an effective drug for making children more comfortable when they have minor illnesses or pain. Understanding and verifying the appropriate doses is critical if parents are to use it safely and successfully. The correct paracetamol dose for a child is determined by their weight. You should always administer the dose specified on the package or bottle based on your child's weight.

Calculating doses -

The usual dose of paracetamol for children is 10-15 mg per kilogram of weight. In other words, if a child weighs 20 kg it should have 10-15mg x 20, which is 200-300 mg. This dose can be taken once every 4 to 6 hours, up to 4 times in 24 hours if needed. In practice, all children's paracetamol products have clear instructions on the container or packaging outlining the correct dose of liquid, tablets or suppositories to give. It's recommended to give the lowest dose that's effective for the shortest period of time. You should not exceed the recommended dose except on the advice of your doctor. No child should take a total of more than 60 mg per kilogram of their body weight in a day. Caution is needed to never exceed the adult dose of paracetamol (4000 mg/day), which can happen if weight-based dosing is applied to children weighing over 65 kg. Paracetamol dosing errors can lead to acute liver failure in children. Calculation of a paracetamol dose in children should be based on body weight rather than age, and regularly updated as children grow. Caregivers should be given clear instructions on how to measure and administer doses. Paracetamol can be prescribed to infants from birth. However, paracetamol has a narrow therapeutic index and infants and children are at increased risk of overdose. Children aged under five years who are acutely unwell are particularly vulnerable to paracetamol toxicity, which can lead to liver failure and death.

Your child's weight	120mg per 5mL	250mg per 5mL
5kg or less	Ask doctor	Ask doctor
6.5kg	4mL	2mL
8kg	5mL	2.5mL
10kg	6mL	3mL
15kg	9mL	4.5mL
20kg	12mL	6mL
30kg	18mL	9mL
40kg	25mL	12mL

Fig 6. Paracetamol Dose for Pediatrics as per weight

CHILD AGE RANGE	DOSE	MAX DOSES/HR	
I-3 months	30-60 mg every 8 hr as necessary	60 mg/kg daily in divided doses	
3-6 months	60 mg every 4-6 hr	4 doses/24 hr	
6 months-2 years	120 mg every 4-6 hr	4 doses/24 hr	
2-4 years	180 mg every 4-6 hr	4 doses/24 hr	
4-6 years	240 mg every 4-6 hr	4 doses/24 hr	
6-8 years	240-250 mg every 4-6 hr	4 doses/24 hr	
8-10 years	360-375 mg every 4-6 hr	4 doses/24 hr	
10-12 years	480-500 mg every 4-6 hr	4 doses/24 hr	
12-16 years	480-750 mg every 4-6 hr	4 doses/24 hr	
16-18 years	500 mg-1 g every 4-6 hr	4 doses/24 hr	

Fig 7. Paracetamol dose for pediatrics as per age Paracetamol Dose for Geriatrics

Paracetamol is the most often used analgesic in the elderly, and it is typically administered in accordance with empirical dosing standards. However, physiological changes associated with aging can impact paracetamol's pharmacokinetics and thus its effects. To evaluate the steps required to achieve more evidence-based paracetamol dose regimens in older individuals, we employed the pediatric research decision tree ideas.

A search was conducted to find research on paracetamol pharmacokinetics and safety in older persons (>60 years) or studies that analyzed pharmacokinetics and/or safety in older adults. Following title and abstract filtering, 259 of the 6088 articles discovered were retained. Further abstract and full-text screening yielded 27 articles, 20 of which described pharmacokinetics and seven safety. These investigations found no difference in absorption with age. When compared to younger subjects, robust older subjects had a lower volume of distribution (Vd) (3.9-22.9%), and weak older respondents had an even lower Vd (20.3%). Similar to Vd, age and frailty reduced paracetamol clearance (29-45.7 and 37.5%, respectively) when compared to younger participants. Because of the sparse and varied evidence, it was impossible to draw solid and relevant conclusions about the increased risk of paracetamol safety in older persons. This review is a first step toward bridging knowledge gaps and transitioning to evidencebased paracetamol dose in older adults. The remaining information gaps include safety when utilizing therapeutic dosages, pharmacokinetic alterations in frail older persons, and to what degree changes in paracetamol pharmacokinetics should lead to a change in dosage in feeble and robust older people.

Age group	Dose given every 4 hours	Dose given every 6 hours	Maximum single dose	Maximum total daily dose of acetaminophen (by all routes)
Adults and adolescents (13 years and older) weighing ≥ 50 kg	650 mg	1000 mg	1000 mg	4000 mg in 24 hours
Adults and adolescents (13 years and older) weighing < 50 kg	12.5 mg/kg	15 mg/kg	15 mg/kg (up to 750 mg)	75 mg/kg in 24 hours (up to 3750 mg)

Fig 8.	Paracetamol	Doses f	for Adults
--------	-------------	---------	------------



age	dose
adults and children 12 years of age and over	20.3 mL (650 mg) every 4 to 6 hours not to exceed 6 doses in a 24-hour period
children 6 to under 12 years of age	10.15 mL (325 mg) every 4 hours not to exceed 5 doses in a 24-hour period
children 4 to under 6 years of age	7.5 mL (240 mg) every 4 hours not to exceed 5 doses in a 24-hour period
children 2 to under 4 years of age	5 mL (160 mg) every 4 hours not to exceed 5 doses in a 24-hour period
children under 2 years of age	consult a doctor

Fig 9. Paracetamol dose as per age group

8	
	<u>Syrup (oral)</u> – 160mg or 5ml
Types of Paracetamol Formulations	For Paediatric:
For Adults:	Tablets – 325mg to 500mg
Tablets – 325mg to 500mg	Oral-disintegrating tablets - 80mg to 160mg
Oral-disintegrating tablets – 80mg to 160mg	Caplets – 325mg, 500mg and 650mg
Caplets – 325mg, 500mg and 650mg	Extended-release caplets – 650mg
Extended-release caplets – 650mg	<u>Capsules</u> – 500mg
<u>Capsules</u> – 500mg	<u>Gel caps / gel tabs</u> – 500mg
<u>Gel caps / gel tabs</u> – 500mg	Oral suspension or solution – 160mg or 5ml
Oral suspension or solution – 160mg or 5ml	Liquid (oral) – 500mg or 5ml
Liquid (oral) – 500mg or 5ml	<u>Syrup (oral)</u> – 160mg or 5ml

Type of paracetamol product	Median amount (IQR)	Range
Solid formulation	22.1 g (5.0-49.0 g)	0–593.0 g
Liquid formulation	0 g (0–0 g)	0-41.5 g
Combination product	0 g (0-4.0g)	0-214.5 g
Expired stock	0 g (0-0 g)	0-105.0 g
Prescribed product	6.0 g (0-45.0 g)	0–610.5 g
Pharmacy OTC product	0 g (0-0 g)	0-84.0 g
Other retailer-sourced	0 g (0–2.5 g)	0-82.0 g
Other source	0 g (0-0 g)	0-5.0 g
Unknown source	0 g (0-0 g)	0-41.0 g
Total	24.0 g (6.0–54.0 g)	0-610.5 g

List of Paracetamol brand names

Brand name	Countries
Acamol	Israel
Acetalgin	Switzerland
Atamel	Venezuela
Adol	Kuwait, Oman
Aldolor	Israel

Alvedon	Sweden
APAP	Poland
Benuron	Germany, Portugal, Switzerland
Biogesic	Philippines
Buscapina	Argentina
Calpol	India
Cemol	Thailand



Crocin	India	
Dafalgan	Belgium, France, Portugal,	
0	Russia, Spain, Switzerland,	
	Ukraine	
Daleron	Slovenia	
Dawaya magi	Kenya	
Depon	Greece	
Dexamol	Israel	
Dolex	Colombia	
Doliprane	France, Portugal, Russia,	
	Ukraine	
Dolprone	Switzerland	
Efferalgan	France, Italy, Portugal,	
	Russia, Spain, Ukraine	
Febricet	Serbia	
FeverAll	United States	
Gelocatil	Spain	
Gripin	Turkey	
Herron	Australia	
Influbene	Switzerland	
Kafa	Switzerland	
Lekadol	Croatia, Slovenia	
Metacin	India	
Milidon	Malaysia	
Pamol	Denmark, Finland,	
	France, Norway	
Panado	South Africa	
Panamax	Australia, United	
D 111	Kingdom	
Panodil	Denmark, Iceland,	
D (Norway, Sweden	
Paracet	Norway	
Paralen	Czech Republic, Slovakia	
Paramed	Botswana, South Africa, Zimbabwe	
Doromol		
Paramol Perdolan	Israel, Taiwan Belgium	
Perfalgan	Germany	
Pinex	Denmark, Iceland,	
I IIICA	Norway	
Plicet	Croatia	
Reliv	Sweden	
Rokamol	Israel	
Sara	Thailand	
Tachipirina	Italy	
Tafirol	Argentina, Mexico	
Tylenol	Brazil, Canada, Japan,	
- ,		

	South Korea, Thailand,
	United States
Tempra	Philippines
Treuphadol	Switzerland
Uphamol	Malaysia
Zolben	Switzerland

DISCUSSION

The proper dosage of paracetamol, a common analgesic and antipyretic drug, was discussed in this review paper. A thorough review of the literature and clinical studies that were available led to the discovery of several important conclusions. First off, people are normally advised to take 500–1000 mg of paracetamol every 4-6 hours, with a daily maximum of 4000 mg. But while figuring out the right dose, individual factors like age, weight, and underlying medical issues should be considered.

Second, it is critical to follow the suggested dosage parameters to reduce the risk of paracetamolrelated side effects, notably hepatotoxicity. Paracetamol overdose can cause serious liver damage and, in extreme cases, death. As a result, healthcare professionals and individuals should take caution and not exceed the recommended daily dose.

Furthermore, special consideration should be specific demographics, given to such as youngsters, the elderly, and those with liver or kidney abnormalities. These groups may require dosage changes or further monitoring to ensure that paracetamol is used safely and effectively. Furthermore, the research emphasized the necessity of educating healthcare professionals and the general public on proper paracetamol dose. Clear and accurate information, together with appropriate labeling and packaging, can help prevent accidents overdoses and enhance patient safety.

CONCLUSION

Lastly, future study should focus on determining the best paracetamol dosage for specific patient



demographics, as well as assessing potential interactions with other drugs. Continued monitoring and surveillance of paracetamol use will help to enhance dose recommendations and reduce dangers. In conclusion, this review paper underlines the importance following of appropriate paracetamol dose guidelines to guarantee safety and efficacy. Understanding the prescribed dosage, taking individual circumstances into account, and raising awareness are all necessary for healthcare professionals and patients to make informed decisions about paracetamol use. Further inquiry is needed.

REFERENCES

- 1. Ulderico Freo, Chiara Ruocco, Alessandra Valerio. Irene Scagnol, Enzo Nisoli. Paracetamol: А Review of Guideline Recommendations, Journal of clinical medicin, 2021 Aug, 10(15), 3420.
- Aronson JK. Ferner RE. Clarification of terminology in drug safety. Drug Safety, 2005, 28, 851–70.

- Jamie J Coleman, Sarah K Pontefract, Adverse drug reactions. Clinical Medicine, 2016, 16(5), 481-485.
- 4. https://www.msdmanuals.com/home/drugs/ad verse-drug-reactions/risk-factors-for-adverse-drug-reactions.
- 5. Brian J Anderson, Paracetamol (Acetaminophen): mechanisms of action. Paediatr Anaesth, 2008, 18(10):915-21.
- 6. KD Tripathi, Essentials of medical pharmacology, Jaypee publication, 5th edition, 2004, page no. 167-184.
- 7. https://bpac.org.nz/2018/paracetamol.aspx
- Paola Mian, Karel Allegaert, Isabel Spriet, Dick Tibboel, Mirko Petrovic. Paracetamol in Older People: Towards Evidence-Based Dosing. Drugs Aging. 2018; 35(7): 603–624.
- 9. https://www.wikidoc.org/index.php/List_of_p aracetamol_brand_names

HOW TO CITE: Kiran Bibave, Atharv Gangarde, Study Of Adverse Drug Reaction Of Paracetamol Dose, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 6, 467-479. https://doi.org/10.5281/zenodo.11521608

